The cardiovascular device business “is a leader in devices for atherectomy, a minimally invasive treatment for plaque build-up in arteries that can restrict blood flow,” according to an Abbott news release. “Procedural use of atherectomy can help maximize the benefits of standard balloon angioplasty or stent treatments in restoring blood flow in complex arterial disease.”
Both boards of directors approved the transaction, and Abbott did not disclose a tentative acquisition date.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
